The authors studied the effects of the dilazep (Cormelian Schering) in the medical management of coronary artery disease (CAD) patients by an open and double-blind study. The treatment consisted of 150 mg/day in the double-blind study and of 300 mg/day in the open study. We also compared the treatment of 150 mg/day versus 300 mg/day. The dilazep reduced the use of TNT and improved anginal pain. The exercise stress test demonstrated that dilazep reduces exercise-induced angina and improved electrocardiographic evidence of myocardial ischemia. A treatment of 300 mg/day gave better results than the treatment of 150 mg/day. It is concluded that dilazep represents useful medical management in the treatment of CAD patients.
|Number of pages||6|
|Publication status||Published - 1980|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine